Karyopharm Therapeutics(US:KPTI)2024-02-29 16:00Financial Performance & Guidance - Karyopharm reported XPOVIO Net Product Revenue of $112 million for FY 2023 and $25 million for Q4 2023[118] - The company anticipates U S XPOVIO Net Product Revenue between $100 million and $120 million in 2024[119] - Karyopharm expects its cash runway to be sufficient to fund planned operations into late 2025[122] - Total revenue was $33.7 million for 4Q 2023 and $146 million for FY 2023[138] Clinical Development Programs - Karyopharm is conducting a Phase 3 trial of selinexor + ruxolitinib in treatment-naïve myelofibrosis (MF)[18] - Preliminary analysis from the Phase 3 SIENDO trial showed encouraging overall survival in the TP53 wild-type exploratory subgroup[29] - The company is planning to report top-line results from the pivotal EC-042 Phase 3 trial in TP53 wildtype endometrial cancer in 1H 2025[141] - Karyopharm is also expecting to report top-line results from the Phase 3 trial of selinexor + ruxolitinib in treatment-naïve MF in 2H 2025[141] Market Opportunity - Karyopharm estimates a potential for ~$2 billion in annual peak U S revenues from selinexor across multiple myeloma, endometrial cancer, and myelofibrosis[16, 20] - Approximately 20,000 people in the U S live with myelofibrosis[25] - In the U S each year, approximately 16,000 patients are diagnosed with advanced and recurrent endometrial cancer[100]